An advisory panel to the FDA voted to recommend the agency approve the sale of a knockoff version of J&J’s arthritis drug Remicade, which had U.S. sales of $4.45 billion last year. The copy was developed by Celltrion and licensed to Pfizer.
from WSJ.com: US Business http://ift.tt/1LfsE5H
via IFTTT
No comments:
Post a Comment